News
Current report No. 18/2021 – Completion of Phase I clinical trial of CPL’280, a second generation GPR40 receptor agonist
Current reports April 1, 2021 Legal basis: Article 17 of the Market Abuse Regulation (MAR) – confidential information.Date: April 1, 2021 08:33 AM With reference to current report No. 13/2020 of April 29, 2020 on the receipt of approval to commence a Phase I clinical trial of the GPR40 receptor agonist, (hereinafter referred to asRead more »
Current report No. 17/2021 – Signing of a co-funding agreement with the National Centre for Research regarding a project for an inhaled drug candidate for the treatment of inflammatory and fibrotic lung diseases, including COVID-19 complications
Current reports March, 31 2021 Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information.Date: March 31, 2021, 08:51 AM Content of the report: With reference to current report No. 7/2021 of February 10, 2021 on the selection by the National Centre for Research and Development (“NCBR”) for co-funding ofRead more »
Celon Pharma Capital Markets Day – 21.04.2021
Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET / 16:00 Warsaw Time Zone. Join Corporate and KOL’s session. Prof. Eduard Vieta Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic and Prof. Jair C. Soares, MD, PhD –Read more »
Current report No. 16/2021 – Receipt of notification regarding change in the Company’s shareholding
Date prepared: March 26, 2021 Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on March 26, 2021 Generali Powszechne Towarzystwo Emerytalne S.A. notified it of a change in the shareholding in the Company; the notification read as follows: “With reference to the information obligation arising from ArticleRead more »
Current report No. 15/2021 – Signature of an agreement with the National Centre for Research and Development for the co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain
Current reports March 24, 2021 Date: March 24, 2021, 08:36 AM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: With reference to current report No. 2/2021 of January 18, 2021 on the selection by the National Centre for Research and Development (“NCBR”) for co-financingRead more »
Celon Pharma in the Stock Exchange Company of the Year ranking
Celon Pharma took 2nd place in the Development prospects category in the 22nd edition of the Stock Exchange Company of the Year 2020. The GSR report was prepared on the basis of an assessment of companies in the course of a special online survey in which companies & nbsp; to be assessed in accordance withRead more »
Current report No. 14/2021 – Adoption of a resolution on the issue of shares as part of increasing its authorized share capital
Current reports March 15, 2021 Date prepared: March 15, 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: With reference to current report No. 9/2021 of February 16, 2021, in which Celon Pharma S.A. (“Company”) announced the adoption of resolutionRead more »
Current report No. 13K– Conclusion of a licence agreement with Glenmark Pharmaceuticals Ltd. – correction
Current reports March 3, 2021 Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information.Time: 3:36 PM Content of the report: The Management Board of Celon Pharma S.A. hereby presents a correction of a clerical error that appeared in the content of current report No. 13/2021 of March 2, 2021, concerningRead more »
Current report No. 13/2021 – Conclusion of a licence agreement with Glenmark Pharmaceuticals Ltd.
Current reports March 2, 2021 Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Time: 6:30 PM Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Bahrain, Oman, Libya, Algeria, Morocco, Iraq, South Africa, Mexico, Peru, Ecuador, Argentina, Canary Islands, Philippines, Malaysia, Thailand, Singapore and Hong Kong. The Management Board of Celon PharmaRead more »
Current report No. 12/2021 – Agreement to terminate cooperation with the company’s current partner in development, manufacturing and commercialisation of an inhalation drug in the US
Current reports March 2, 2021 Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Time: 6:06 PM Content of the report: In relation to the information provided in the Prospectus of Celon Pharma S.A. (the “Company”) approved by the Polish Financial Supervision Authority on August 29, 2016 and toRead more »